Dose first patient in global confirmatory Phase 3 study
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 24 Feb 2026
- Due
- 30 Jun 2026
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“dosing of first patient expected mid-2026”
What we found
Evidence strength A What the grades mean
The company failed to dose the first patient in its global confirmatory Phase 3 study by the mid-2026 deadline, subsequently updating its guidance to the third quarter of 2026.
-
A Larimar Therapeutics, Inc. 8-K filed 2026-08-04
“Global Confirmatory Phase 3 Study: Dosing of first patient expected Q3 2026.” ✓ confirmed on the page
-
A Larimar Therapeutics, Inc. 10-Q filed 2026-08-04
“We plan to initiate dosing of the first patient in the third quarter of 2026.” ✓ confirmed on the page
Market reaction: the shares moved +4.1% against the S&P 500 over the three sessions around the disclosure (3 Aug 2026 to 6 Aug 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- Dosing of first patient
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-LRMR-003079 · Corrections policy